ManagementManagementManagementManagement
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 25, 2013 9:00am EDT

Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100

Nov 27, 2012 9:00am EST

Lixte Biotechnology Holdings Announces New Appointment To Board Of Directors

Jul 31, 2012 9:00am EDT

Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100

May 01, 2012 12:00pm EDT

Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound

Apr 04, 2012 9:30am EDT

Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor

Jan 09, 2012 9:00am EST

Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases

Dec 19, 2011 9:00am EST

Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease

Sep 22, 2011 9:00am EDT

Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound

May 25, 2011 9:00am EDT

Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

Mar 02, 2011 10:39am EST

Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government

  • Previous
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com

LIXTE Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About LIXTE
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2023 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. Site by Third Eye Industries
    Close